Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKYANASDAQ:BNGONASDAQ:LABNASDAQ:SEER On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKYAAkoya Biosciences$1.22-3.9%$1.22$0.93▼$3.42$60.85M1.34391,709 shs177,729 shsBNGOBionano Genomics$3.70-1.9%$3.72$2.68▼$61.80$12.45M2.36105,139 shs60,166 shsLABStandard BioTools$1.09+5.8%$1.11$0.92▼$2.65$414.01M1.82.14 million shs2.10 million shsSEERSeer$1.99+1.5%$1.94$1.56▼$2.63$118.97M1.58330,843 shs263,141 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKYAAkoya Biosciences-3.94%-6.15%-6.87%-26.06%-46.96%BNGOBionano Genomics-1.86%+2.21%-14.94%-15.53%-94.01%LABStandard BioTools+5.83%+4.81%-7.63%+4.31%-56.92%SEERSeer+1.53%-4.33%+1.53%-9.55%+5.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKYAAkoya Biosciences1.4165 of 5 stars3.01.00.00.01.81.70.6BNGOBionano Genomics1.6041 of 5 stars3.12.00.00.02.90.00.6LABStandard BioTools3.1027 of 5 stars3.33.00.00.02.84.20.6SEERSeer1.5596 of 5 stars3.01.00.00.01.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKYAAkoya Biosciences 2.00Hold$2.51105.41% UpsideBNGOBionano Genomics 2.25Hold$7.0089.19% UpsideLABStandard BioTools 2.50Moderate Buy$2.50129.36% UpsideSEERSeer 2.00Hold$3.0050.75% UpsideCurrent Analyst Ratings BreakdownLatest BNGO, LAB, SEER, and AKYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025AKYAAkoya BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$1.80 ➝ $1.084/29/2025AKYAAkoya BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$3.50 ➝ $1.804/14/2025AKYAAkoya BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$2.40 ➝ $1.654/9/2025BNGOBionano GenomicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.004/2/2025BNGOBionano GenomicsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$1.00 ➝ $4.003/25/2025AKYAAkoya BiosciencesStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$3.50 ➝ $1.803/18/2025AKYAAkoya BiosciencesStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$3.50 ➝ $3.503/5/2025AKYAAkoya BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$2.40(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKYAAkoya Biosciences$79.96M0.76N/AN/A$1.10 per share1.11BNGOBionano Genomics$28.46M0.44N/AN/A$125.85 per share0.03LABStandard BioTools$169.69M2.44N/AN/A($1.85) per share-0.59SEERSeer$15.06M7.90N/AN/A$6.17 per share0.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKYAAkoya Biosciences-$63.32M-$0.97N/AN/AN/A-66.77%-162.99%-32.76%8/4/2025 (Estimated)BNGOBionano Genomics-$232.49M-$138.92N/A∞N/A-407.34%-154.45%-80.78%8/6/2025 (Estimated)LABStandard BioTools-$74.66M-$0.35N/AN/AN/A-79.92%-27.05%-15.52%7/30/2025 (Estimated)SEERSeer-$86.28M-$1.41N/AN/AN/A-565.83%-21.96%-19.85%8/14/2025 (Estimated)Latest BNGO, LAB, SEER, and AKYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025BNGOBionano Genomics-$3.49-$1.15+$2.34-$1.15$6.25 million$6.46 million5/13/2025Q1 2025SEERSeer-$0.37-$0.34+$0.03-$0.34$3.25 million$4.21 million5/12/2025Q1 2025AKYAAkoya Biosciences-$0.29-$0.32-$0.03-$0.32$20.19 million$16.64 million3/17/2025Q4 2024AKYAAkoya Biosciences-$0.15-$0.17-$0.02-$0.17$21.34 million$21.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKYAAkoya BiosciencesN/AN/AN/AN/AN/ABNGOBionano GenomicsN/AN/AN/AN/AN/ALABStandard BioToolsN/AN/AN/AN/AN/ASEERSeerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKYAAkoya Biosciences5.622.751.85BNGOBionano Genomics0.071.430.99LABStandard BioToolsN/A3.763.41SEERSeerN/A18.3617.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKYAAkoya Biosciences79.42%BNGOBionano Genomics11.35%LABStandard BioTools53.74%SEERSeer75.20%Insider OwnershipCompanyInsider OwnershipAKYAAkoya Biosciences7.30%BNGOBionano Genomics1.60%LABStandard BioTools23.16%SEERSeer15.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKYAAkoya Biosciences9049.88 million45.95 millionOptionableBNGOBionano Genomics3003.36 million1.92 millionOptionableLABStandard BioTools620379.82 million174.59 millionOptionableSEERSeer16059.78 million50.12 millionOptionableBNGO, LAB, SEER, and AKYA HeadlinesRecent News About These CompaniesYounger Adults See Rising Pancreatic & Colorectal Cancer RatesMay 27 at 10:51 PM | targetedonc.comPuri seer’s security to be enhancedMay 25, 2025 | thehansindia.comKarnataka: Belagavi Math Head Seer Arrested On Charges Of Raping 17-Year-Old GirlMay 25, 2025 | oneindia.comGrand procession marks Namma Basava JayantiMay 24, 2025 | starofmysore.comPolice arrested a seer in rape case of a minorMay 24, 2025 | timesofindia.indiatimes.comSeer Arrested For Kidnapping, Raping 17-Year-Old In Karnataka: CopsMay 24, 2025 | msn.com‘Namma Basava Jayanti’ from tomorrowMay 23, 2025 | starofmysore.comProperty of notorious drug peddler attached in Anantnag: PoliceMay 23, 2025 | risingkashmir.comYogi cites seer’s prophecy, says Pakistan's 'end' is very nearMay 23, 2025 | deccanherald.comLiving Nostradamus predicts Royal Family will be hit with 'ticking time bomb' crisisMay 23, 2025 | msn.comJane Opoku Agyemang: Karma Seer Drops Prophecy About The Vice PresidentMay 23, 2025 | msn.comGhanian seer shares prophecy about Davido and Chioma’s marriageMay 22, 2025 | gistreel.comScary prophecy about Davido’s marriage worries fans, seer says “Chioma needs traditional prayers”May 22, 2025 | msn.comSeer Gyan reveals winner of 2024/2025 Ghana Premier League amid the tight raceMay 21, 2025 | ghanaweb.comProphet Who Predicted Junior Pope’s Death Makes Disturbing Prophecy on Lamine YamalMay 21, 2025 | msn.comAl Seer Marine inks $13mln production deal with Albwardy DamenMay 21, 2025 | zawya.comAl-Seer Marine wins $13m deal for interceptor vesselsMay 21, 2025 | meed.comAl Seer Marine awarded AED47.6 million contract to deliver high-speed interceptor vesselsMay 21, 2025 | msn.comDada KD Dies: Karma President's Prophecy About Ghanaian Musician Comes To PassMay 21, 2025 | msn.comDark prophecy from Ghanaian seer casts shadow over Lamine Yamal’s bright futureMay 21, 2025 | msn.comJacobs Levy Equity Management Inc. Has $374,000 Stock Position in Seer, Inc. (NASDAQ:SEER)May 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesRocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsBy Ryan Hasson | May 5, 2025View Rocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsOklo Reaches Critical Mass, Atomic Upside Still AvailableBy Thomas Hughes | May 14, 2025View Oklo Reaches Critical Mass, Atomic Upside Still AvailableRocket Lab: Earnings Miss But Neutron Momentum HoldsBy Ryan Hasson | May 12, 2025View Rocket Lab: Earnings Miss But Neutron Momentum HoldsHims & Hers Stock Soars on Novo Nordisk CollaborationBy Gabriel Osorio-Mazilli | April 30, 2025View Hims & Hers Stock Soars on Novo Nordisk CollaborationRetail Investors Are Betting Big on Rocket Lab—Should You Too?By Ryan Hasson | May 16, 2025View Retail Investors Are Betting Big on Rocket Lab—Should You Too?BNGO, LAB, SEER, and AKYA Company DescriptionsAkoya Biosciences NASDAQ:AKYA$1.22 -0.05 (-3.94%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$1.22 0.00 (0.00%) As of 05/28/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.Bionano Genomics NASDAQ:BNGO$3.70 -0.07 (-1.86%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$3.66 -0.04 (-0.95%) As of 05/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.Standard BioTools NASDAQ:LAB$1.09 +0.06 (+5.83%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$1.10 +0.01 (+1.28%) As of 05/28/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.Seer NASDAQ:SEER$1.99 +0.03 (+1.53%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$1.98 0.00 (-0.25%) As of 05/28/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
